BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Aflibercept: trial readouts and FDA decisions
3 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 10 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Kyowa Kirin Co., Ltd., AbbVie, EyePoint Pharmaceuticals, Inc., Qilu Pharmaceutical Co., Ltd., Adverum Biotechnologies, Inc., Ocular Therapeutix, Inc., Beijing Anlong Biopharmaceutical Co., Ltd., Kodiak Sciences Inc. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT07489586 A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration | Neovascular Age-Related Macular Degeneration (nAMD) | not yet recruiting | 356 |
| 2026-12-22 est. | P3 | Adverum Biotechnologies, Inc. | NCT06856577 Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration | Neovascular Age-Related Macular Degeneration (nAMD); Wet AMD | active not recruiting | 311 |
| 2027-01-08 est. | P3 | Ocular Therapeutix, Inc. OCUL | NCT06495918 Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | Neovascular Age-related Macular Degeneration | active not recruiting | 825 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-31 est. | P2 | Kyowa Kirin Co., Ltd. | NCT06116916 Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema | Diabetic Macular Edema (DME) | active not recruiting | 185 |
| 2026-10 est. | P3 | AbbVie ABBV | NCT05407636 Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD | AMD; nAMD; Wet Age-related Macular Degeneration; wAMD; WetAMD; CNV | active not recruiting | 735 |
| 2026-09-30 est. | P2 | Beijing Anlong Biopharmaceutical Co., Ltd. | NCT06839339 Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD | Wet Age-related Macular Degeneration (wAMD) | not yet recruiting | 40 |
| 2026-09-09 | P3 | EyePoint Pharmaceuticals, Inc. EYPT | NCT06683742 A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 | Wet Age Related Macular Degeneration; wAMD | active not recruiting | 400 |
| 2026-09-02 | P3 | Kodiak Sciences Inc KOD | NCT06556368 A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-re | Wet Age-related Macular Degeneration | active not recruiting | 667 |
| 2026-09 est. | P3 | Salutaris Medical Devices, Inc. | NCT05251636 Adjunct Episcleral Brachytherapy for PCV | Age-Related Macular Degeneration; Polypoid Choroidal Vasculopathy | not yet recruiting | 159 |
| 2026-07-13 | P3 | EyePoint Pharmaceuticals, Inc. EYPT | NCT06668064 A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 | Wet Age Related Macular Degeneration; wAMD | active not recruiting | 400 |
| 2026-06-18 | P2 | AbbVie ABBV | NCT04567550 RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular | Diabetic Retinopathy (DR); Center-Involved Diabetic Macular Edema (CI-DME) | completed | 139 |
| 2026-06-03 | P2 | Kyowa Kirin Co., Ltd. | NCT06116890 Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration | Neovascular Age-Related Macular Degeneration (nAMD) | completed | 170 |
| 2026-06 est. | P3 | RemeGen Co., Ltd. | NCT05885503 Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema | Diabetic Macular Edema | unknown | 316 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.